1997•PubMedRequires access

[Clinical study on reversal of multidrug resistance in refractory and relapsed acute leukemias by cyclosporin A].

X.C. Li, Wu J, L Zhang, Hong Zhu

Abstract

OBJECTIVE: To explore the clinical implication of reversal of multidrug resistance (MDR) by cyclosporin A (CsA) in refractory and relapsed acute leukemias. METHODS: The expression of p170 was assayed by immunocytochemical method (Avidin-Biotin Complex, ABC) using a monoclonal antibody JSB-1 against P-170. The P-170 positive cases were randomly divided into two groups:trial group (with CsA as revertant) and control group (without CsA), and the blood concentration of CsA was detected by HPLC. RESULTS: The complete remission rates were 53% and 20% in trial and control group, respectively (P<0.05), and the reversing effect was positively correlated with blood concentration of CsA. CONCLUSION: CsA might be a safe and effective revertant, and can be applied in the treatment of refractory and relapsed acute leukemia.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Refractory (planetary science), Acute leukemia, Medicine, Multiple drug resistance, Monoclonal antibody, Clinical trial, Internal medicine, Complete remission